Leflunomide side effects: what 104,025 FDA adverse event reports show
Drug class
Antirheumatic Agent
Who reports
104,025 reports · 82% serious · 9,331 with death outcome · 82% female
Used for
Leflunomide tablets are indicated for the treatment of adults with active rheumatoid arthritis (RA). Leflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of adults with active rheumatoid arthritis.
What it is
Leflunomide is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline.
Boxed warning
EMBRYO-FETAL TOXICITY and HEPATOTOXICITY WARNING: EMBRYO-FETAL TOXICITY and HEPATOTOXICITY Embryo-Fetal Toxicity Leflunomide is contraindicated for use in pregnant women because of the potential for fetal harm. Teratogenicity and embryo-lethality occurred in animals administered leflunomide at doses lower than the human exposure level.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,229 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Anti-cyclic citrullinated peptide antibody positive | 6,127 | 1,365.5 1,273.0–1,464.7ROR 1,450.9 · calibrated p 3e-19 ✓ | 173.6 EB05 170.0 · IC025 +7.4 3/3 methods agree | Lab value / disease marker | serious PRR 121.6 · 92% clinician | no trial arm names this drug |
| Rheumatoid factor negative | 151 | 1,245.1 809.4–1,915.4ROR 1,246.9 · calibrated p 4e-17 ✓ | 168.0 EB05 146.7 · IC025 +6.5 3/3 methods agree | Reporting / coding artifact | serious n=151 · ♀ 49% (drug 82%) | no trial arm names this drug |
| Red blood cell sedimentation rate | 219 | 734.6 551.1–979.2ROR 736.1 · calibrated p 3e-15 ✓ | 154.6 EB05 138.2 · IC025 +6.6 3/3 methods agree | Lab value / disease marker | serious n=219 · 91% clinician | no trial arm names this drug |
| Rheumatoid factor positive | 4,432 | 694.5 652.6–739.0ROR 725.3 · calibrated p 1e-15 ✓ | 154.7 EB05 150.9 · IC025 +7.2 3/3 methods agree | Lab value / disease marker | serious n=4,428 · 91% clinician | no trial arm names this drug |
| Pemphigus | 9,382 | 642.9 616.9–670.0ROR 706.5 · calibrated p 1e-15 ✓ | 152.0 EB05 149.5 · IC025 +7.2 3/3 methods agree | Not in label — unassessed | serious PRR 106.5 | no trial arm names this drug |
| Swollen joint count increased | 2,321 | 606.0 558.4–657.6ROR 619.8 · calibrated p 6e-15 ✓ | 149.8 EB05 144.7 · IC025 +7.1 3/3 methods agree | Lab value / disease marker | serious n=2,319 · 94% clinician | no trial arm names this drug |
| Rheumatic fever | 3,226 | 587.9 549.0–629.6ROR 606.7 · calibrated p 7e-15 ✓ | 148.7 EB05 144.4 · IC025 +7.1 3/3 methods agree | Labeled (related wording) related wording | serious n=3,225 · 94% clinician | no trial arm names this drug |
| Duodenal ulcer perforation | 5,149 | 485.9 462.0–511.1ROR 511.2 · calibrated p 5e-14 ✓ | 141.3 EB05 138.1 · IC025 +7.1 3/3 methods agree | Not in label — unassessed | serious PRR 98.5 · 93% clinician | no trial arm names this drug |
| C-reactive protein | 620 | 444.6 385.8–512.2ROR 447.2 · calibrated p 2e-13 ✓ | 137.1 EB05 128.2 · IC025 +6.8 3/3 methods agree | Lab value / disease marker | serious n=620 · 95% clinician | no trial arm names this drug |
| Deep vein thrombosis postoperative | 1,325 | 429.2 390.0–472.2ROR 434.7 · calibrated p 3e-13 ✓ | 135.9 EB05 129.8 · IC025 +6.9 3/3 methods agree | Not in label — unassessed | serious n=1,325 · 92% clinician | no trial arm names this drug |
| Lupus vulgaris | 781 | 392.3 347.6–442.7ROR 395.2 · calibrated p 7e-13 ✓ | 131.8 EB05 124.2 · IC025 +6.8 3/3 methods agree | Not in label — unassessed | serious n=781 · 95% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody | 431 | 374.1 318.7–439.2ROR 375.7 · calibrated p 1e-12 ✓ | 129.4 EB05 119.4 · IC025 +6.7 3/3 methods agree | Lab value / disease marker | serious n=431 · 94% clinician | no trial arm names this drug |
| Swollen joint count | 158 | 367.9 282.6–478.8ROR 368.4 · calibrated p 3e-12 ✓ | 127.4 EB05 111.6 · IC025 +6.3 3/3 methods agree | Not in label — unassessed | serious n=158 · 100% clinician | no trial arm names this drug |
| Hand deformity | 8,389 | 367.0 354.1–380.3ROR 399.1 · calibrated p 6e-13 ✓ | 129.2 EB05 126.9 · IC025 +7.0 3/3 methods agree | Not in label — unassessed | serious PRR 97.9 | no trial arm names this drug |
| Facet joint syndrome | 2,008 | 360.0 334.6–387.3ROR 367.0 · calibrated p 1e-12 ✓ | 128.2 EB05 123.5 · IC025 +6.9 3/3 methods agree | Not in label — unassessed | serious n=2,008 · 95% clinician | no trial arm names this drug |
| Grip strength | 146 | 348.1 265.9–455.7ROR 348.6 · calibrated p 5e-12 ✓ | 124.8 EB05 108.7 · IC025 +6.2 3/3 methods agree | Not in label — unassessed | serious n=146 · 100% clinician | no trial arm names this drug |
| Hepatic enzyme | 85 | 317.4 225.2–447.3ROR 317.7 · calibrated p 2e-11 ✓ | 119.3 EB05 99.5 · IC025 +5.8 3/3 methods agree | Labeled (related wording) related wording | serious n=84 · 100% clinician | no trial arm names this drug |
| C-reactive protein abnormal | 3,855 | 309.0 293.9–324.9ROR 320.9 · calibrated p 5e-12 ✓ | 121.2 EB05 118.0 · IC025 +6.8 3/3 methods agree | Lab value / disease marker | serious n=3,854 | no trial arm names this drug |
| Granuloma skin | 496 | 304.8 265.0–350.7ROR 306.3 · calibrated p 1e-11 ✓ | 120.1 EB05 111.4 · IC025 +6.6 3/3 methods agree | Not in label — unassessed | serious n=496 | no trial arm names this drug |
| Musculoskeletal deformity | 136 | 277.5 213.9–360.0ROR 277.8 · calibrated p 4e-11 ✓ | 114.3 EB05 99.0 · IC025 +6.1 3/3 methods agree | Not in label — unassessed | serious n=136 · 100% clinician | no trial arm names this drug |
| Synovitis | 10,363 | 275.3 267.4–283.5ROR 305.7 · calibrated p 8e-12 ✓ | 115.7 EB05 113.8 · IC025 +6.8 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 84.3 | no trial arm names this drug |
| Red blood cell sedimentation rate abnormal | 1,321 | 267.9 246.6–290.9ROR 271.3 · calibrated p 3e-11 ✓ | 114.2 EB05 109.1 · IC025 +6.7 3/3 methods agree | Lab value / disease marker | serious n=1,320 | no trial arm names this drug |
| X-ray abnormal | 945 | 228.9 208.5–251.3ROR 231.0 · calibrated p 1e-10 ✓ | 106.5 EB05 100.9 · IC025 +6.6 3/3 methods agree | Lab value / disease marker | serious n=945 · 93% clinician | no trial arm names this drug |
| Adjustment disorder with depressed mood | 1,042 | 217.5 199.2–237.5ROR 219.7 · calibrated p 2e-10 ✓ | 104.0 EB05 98.8 · IC025 +6.5 3/3 methods agree | Not in label — unassessed | serious n=1,041 · 95% clinician | no trial arm names this drug |
| Muscle injury | 4,227 | 215.9 206.8–225.5ROR 225.0 · calibrated p 1e-10 ✓ | 103.7 EB05 101.1 · IC025 +6.6 3/3 methods agree | Not in label — unassessed | serious PRR 78.5 · 94% clinician | no trial arm names this drug |
| Helicobacter infection | 5,181 | 210.1 202.1–218.3ROR 221.0 · calibrated p 2e-10 ✓ | 102.4 EB05 100.1 · IC025 +6.6 3/3 methods agree | Not in label — unassessed | serious PRR 75.5 · 93% clinician | no trial arm names this drug |
| Dislocation of vertebra | 1,106 | 200.8 184.7–218.3ROR 203.0 · calibrated p 4e-10 ✓ | 100.0 EB05 95.2 · IC025 +6.5 3/3 methods agree | Not in label — unassessed | serious n=1,106 · 94% clinician | no trial arm names this drug |
| Hypocholesterolaemia | 152 | 197.9 158.1–247.8ROR 198.2 · calibrated p 7e-10 ✓ | 98.3 EB05 85.8 · IC025 +6.0 3/3 methods agree | Not in label — unassessed | serious n=152 · 100% clinician | no trial arm names this drug |
| Sleep disorder due to general medical condition, insomnia type | 3,116 | 190.4 181.3–199.9ROR 196.2 · calibrated p 5e-10 ✓ | 97.5 EB05 94.6 · IC025 +6.5 3/3 methods agree | Not in label — unassessed | serious n=3,113 · 93% clinician | no trial arm names this drug |
| Folliculitis | 4,922 | 184.7 177.8–192.0ROR 193.9 · calibrated p 5e-10 ✓ | 96.0 EB05 93.8 · IC025 +6.5 3/3 methods agree | Not in label — unassessed | serious PRR 78.6 · 94% clinician | no trial arm names this drug |
| Bone erosion | 1,595 | 166.0 155.3–177.3ROR 168.5 · calibrated p 2e-9 ✓ | 90.6 EB05 87.0 · IC025 +6.4 3/3 methods agree | Not in label — unassessed | serious n=1,590 | no trial arm names this drug |
| Retinitis | 683 | 140.1 127.0–154.5ROR 141.0 · calibrated p 8e-9 ✓ | 82.3 EB05 77.2 · IC025 +6.2 3/3 methods agree | Not in label — unassessed | serious n=683 · 94% clinician | no trial arm names this drug |
| Joint laxity | 123 | 138.3 109.9–174.1ROR 138.5 · calibrated p 1e-8 ✓ | 80.8 EB05 69.5 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious n=122 | no trial arm names this drug |
| Rheumatoid nodule | 1,120 | 136.1 126.1–146.8ROR 137.5 · calibrated p 1e-8 ✓ | 80.9 EB05 77.0 · IC025 +6.2 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=1,102 | no trial arm names this drug |
| Contraindicated product administered | 11,938 | 132.5 129.6–135.5ROR 149.6 · calibrated p 5e-9 ✓ | 79.8 EB05 78.6 · IC025 +6.3 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 107.6 · serious PRR 68.7 | no trial arm names this drug |
| Subcutaneous drug absorption impaired | 213 | 129.7 109.1–154.2ROR 130.0 · calibrated p 2e-8 ✓ | 78.2 EB05 69.8 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious n=213 · 100% clinician | no trial arm names this drug |
| Glossodynia (burning tongue/mouth pain) | 8,702 | 128.9 125.5–132.3ROR 140.6 · calibrated p 8e-9 ✓ | 78.4 EB05 77.1 · IC025 +6.3 3/3 methods agree | Labeled (related wording) related wording | serious PRR 79.1 · 90% clinician | no trial arm names this drug |
| Blood parathyroid hormone decreased | 576 | 127.2 114.6–141.2ROR 127.9 · calibrated p 2e-8 ✓ | 77.6 EB05 72.5 · IC025 +6.1 3/3 methods agree | Lab value / disease marker | serious n=576 | no trial arm names this drug |
| Peripheral venous disease | 1,527 | 125.1 117.4–133.4ROR 127.0 · calibrated p 2e-8 ✓ | 77.0 EB05 73.8 · IC025 +6.1 3/3 methods agree | Labeled (related wording) related wording | serious n=1,526 · 94% clinician | no trial arm names this drug |
| Pericarditis | 6,347 | 124.4 120.6–128.3ROR 132.4 · calibrated p 1e-8 ✓ | 76.7 EB05 75.2 · IC025 +6.2 3/3 methods agree | Not in label — unassessed | serious PRR 54.0 · 93% clinician | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Liver injury | 14,280 | 10.09.8–10.1 | signal |
| Interstitial lung disease | 4,061 | 8.98.6–9.1 | signal |
| Tendon disorder | 831 | 4.54.2–4.8 | signal |
| Serious infection | 15,390 | 4.14.0–4.1 | signal |
| Opportunistic infection | 2,477 | 3.73.6–3.9 | signal |
| Hyperglycaemia / diabetes | 5,292 | 3.13.0–3.2 | signal |
| Anaphylaxis / angioedema | 1,480 | 2.42.3–2.5 | signal |
| Depression | 3,291 | 2.42.3–2.5 | signal |
| Fall / fracture | 3,749 | 2.01.9–2.1 | raised |
| Pancreatitis | 696 | 1.71.6–1.9 | raised |
| Anaemia | 2,234 | 1.51.4–1.6 | raised |
| Malignancy | 2,564 | 1.41.3–1.4 | raised |
| Venous thromboembolism | 1,460 | 1.41.3–1.4 | raised |
| Osteonecrosis | 376 | 1.31.2–1.5 | raised |
| Rhabdomyolysis / myopathy | 496 | 1.21.1–1.3 | raised |
| Kidney injury | 2,752 | 1.21.2–1.3 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 37,382 | 5.9 5.8–5.9ROR 8.6 · calibrated p 0.053 | 5.7 EB05 5.7 · IC025 +2.5 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 6.4 · serious PRR 10.2 | no trial arm names this drug |
| Rheumatoid arthritis | 25,338 | 58.1 57.4–58.9ROR 76.5 · calibrated p 8e-7 ✓ | 45.2 EB05 44.7 · IC025 +5.5 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 46.1 · serious PRR 37.7 | no trial arm names this drug |
| Pain | 20,469 | 6.9 6.8–7.0ROR 8.4 · calibrated p 0.058 | 6.7 EB05 6.6 · IC025 +2.7 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 6.3 · serious PRR 7.0 | no trial arm names this drug |
| Arthralgia (joint pain) | 17,392 | 8.8 8.7–8.9ROR 10.4 · calibrated p 0.029 ✓ | 8.5 EB05 8.4 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | age-adj. PRR 7.8 · serious PRR 10.2 | no trial arm names this drug |
| Drug intolerance | 15,935 | 39.9 39.3–40.5ROR 46.9 · calibrated p 2e-5 ✓ | 33.4 EB05 32.9 · IC025 +5.0 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 42.7 · serious PRR 37.1 | no trial arm names this drug |
| Joint swelling | 15,925 | 30.6 30.1–31.1ROR 36.0 · calibrated p 1e-4 ✓ | 26.6 EB05 26.3 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | age-adj. PRR 25.9 · serious PRR 31.2 | no trial arm names this drug |
| Fatigue (tiredness) | 15,756 | 4.2 4.1–4.2ROR 4.7 · calibrated p 0.268 | 4.1 EB05 4.0 · IC025 +2.0 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 3.5 · serious PRR 5.2 | no trial arm names this drug |
| Rash | 13,723 | 6.6 6.5–6.7ROR 7.4 · calibrated p 0.084 | 6.4 EB05 6.3 · IC025 +2.6 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 6.2 · serious PRR 9.4 | no trial arm names this drug |
| Off label use (used outside approved label) | 12,216 | 2.9 2.8–2.9ROR 3.1 · calibrated p 0.591 | 2.8 EB05 2.8 · IC025 +1.5 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 2.9 · serious PRR 3.6 | no trial arm names this drug |
| Abdominal discomfort | 12,046 | 15.6 15.3–15.9ROR 17.5 · calibrated p 0.004 ✓ | 14.5 EB05 14.3 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | age-adj. PRR 12.7 · serious PRR 22.2 | no trial arm names this drug |
| Alopecia (hair loss) | 11,999 | 13.0 12.8–13.3ROR 14.6 · calibrated p 0.008 ✓ | 12.3 EB05 12.1 · IC025 +3.6 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 9.8 · serious PRR 17.5 | no trial arm names this drug |
| Contraindicated product administered | 11,938 | 132.5 129.6–135.5ROR 149.6 · calibrated p 5e-9 ✓ | 79.8 EB05 78.6 · IC025 +6.3 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 107.6 · serious PRR 68.7 | no trial arm names this drug |
| Arthropathy | 11,100 | 50.0 49.0–51.0ROR 55.8 · calibrated p 7e-6 ✓ | 40.1 EB05 39.5 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 44.9 · serious PRR 33.9 | no trial arm names this drug |
| Condition aggravated | 10,659 | 7.3 7.2–7.5ROR 8.1 · calibrated p 0.065 | 7.1 EB05 7.0 · IC025 +2.8 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 6.8 · serious PRR 7.3 | no trial arm names this drug |
| Swelling | 10,563 | 25.6 25.1–26.1ROR 28.4 · calibrated p 3e-4 ✓ | 22.8 EB05 22.4 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | age-adj. PRR 20.7 · serious PRR 25.4 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Pemphigus — n=9,382, PRR 642.9
- Duodenal ulcer perforation — n=5,149, PRR 485.9
- Deep vein thrombosis postoperative — n=1,325, PRR 429.2
- Lupus vulgaris — n=781, PRR 392.3
- Swollen joint count — n=158, PRR 367.9
- Hand deformity — n=8,389, PRR 367.0
- Facet joint syndrome — n=2,008, PRR 360.0
- Grip strength — n=146, PRR 348.1
- Granuloma skin — n=496, PRR 304.8
- Musculoskeletal deformity — n=136, PRR 277.5
✓ A hand-written Bradford Hill causality assessment exists for this drug: Leflunomide ↔ Hepatotoxicity.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Leflunomide?
In FDA FAERS, the most frequently co-reported reaction terms for Leflunomide are rheumatoid arthritis, pain, arthralgia, joint swelling, fatigue, rash. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Leflunomide have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: EMBRYO-FETAL TOXICITY and HEPATOTOXICITY WARNING: EMBRYO-FETAL TOXICITY and HEPATOTOXICITY Embryo-Fetal Toxicity Leflunomide is contraindicated for use in pregnant women because of the potential for fetal harm. Teratogenicity and embryo-lethality occurred in animals administered leflunomide at doses lower than the human exposure level.
Do FAERS signals prove that Leflunomide causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 2b5f387e-b52b-ad80-e063-6394a90a56d5, effective 20250110; matched on
openfda.generic_name.exact:"LEFLUNOMIDE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 3899 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,269 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
LEFLUNOMIDE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.